Explore the latest in melanoma, including advances in screening, prevention, diagnosis, and management of local and metastatic disease.
This study compares pathogenic variant detection accuracy in cancer-disposition genes of prostate cancer and melanoma cohort biopsy samples using deep learning vs standard genetic analysis methods.
This cost-utility analysis compares the cost-utility of these novel agents and their combinations with or without BRAF gene testing guidance for treating newly diagnosed advanced melanoma with unknown BRAF status.
This retrospective cohort study analyzes data from the National Cancer Database regarding outcomes of Mohs micrographic surgery versus wide local excision in treatment of melanomas that occur in the trunk and extremities.
This review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights results from clinical trials exploring these approaches.
This observational cohort study assesses the incidence of new cutaneous melanoma in patients treated with ipilimumab, nivolumab, and/or pembrolizumab for metastatic melanoma.
This cohort study examines the sociodemographic factors associated with immunotherapy receipt in patients with metastatic melanoma in the era of immune checkpoint inhibitors and the Patient Protection and Affordable Care Act in the US.
This systematic review and meta-analysis assesses the performance of commercially available gene expression profile tests for prognosis of cutaneous melanoma in patients with stage I or stage II melanoma
This cohort study examines whether anti–programmed cell death 1 antibody (anti–PD-1) therapy is associated with reduced risk of recurrence of toxic effects in patients with metastatic melanoma who experienced severe immune-related adverse effects (AEs) after receipt of ipilimumab therapy.
This consensus statement assesses what evidence is needed to develop guidelines on integration of gene expression profile testing into cutaneous melanoma management.
This cohort study examines whether MUC16 mutation is associated with response to treatment with immune checkpoint inhibitors and outcomes among patients with solid tumors, non–small cell lung cancer, and melanoma.
This Viewpoint discusses thin melanoma and the current evidence on the use of gene expression profile testing to guide treatment and follow-up care.
This cohort study examines the potential association of the use of immune checkpoint inhibitors with testicular histopathologic conditions.
This post hoc subgroup analysis examines the results of 3 randomized clinical trials to assess the association of BRAF V600E/K mutation status and previous BRAF inhibitor and MEK inhibitor therapy with response to treatment with pembrolizumab in patients with advanced melanoma.
This cohort study evaluates the association of race, ethnicity, and socioeconomic status with treatment and survival in patients with uveal melanoma.
This cohort study examines the association of innovations in radiotherapy techniques and systemic treatment with clinical outcomes among Canadian patients with melanoma brain metastasis between 2007 and 2016.
This systematic review and meta-analysis examines whether biologic treatment of inflammatory bowel disease, rheumatoid arthritis, or psoriasis is associated with increased risk of melanoma compared with conventional systemic therapy.
This cohort study uses data from 41 European cancer registries to estimate the incidence and survival of patients with conjunctival melanoma in Europe.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: